We report two cases of meningococcal septic shock with multiple organ failure treated with prompt administration of activated protein C. This was associated with a rapid clinical improvement and early cessation of organ support. Both patients survived to hospital discharge with no long-term sequelae.
FisherC.J., YanS.B.Protein C levels as a prognostic indicator of outcomes in sepsis and related diseases. Crit Care Med2000; 28: S49–56.
2.
BernardG.R., VincentJ.L., LaterreP.F.Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med2001; 344: 699–709.
3.
SiegelJ.P.Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med2002; 347: 1030–1034.
4.
YanS.B., DhainautJ.F.Activated protein C versus protein C in severe sepsis. Crit Care Med2001; 29: S69–74.
5.
BoldtJ., PapsdorfM., RotheA., KumleB., PiperS.Changes of the hemostatic network in critically ill patients—is there a difference between sepsis, trauma, and neurosurgery patients?Crit Care Med2000; 28: 445–450.
6.
PowarsD., LarsenR., JohnsonJ.Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis1993; 17: 254–261.
7.
FijnvandraatK., DerkxB., PetersM.Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost1995; 73: 15–20.
8.
WhiteB., LivingstoneW., MurphyC., HodgsonA., RaffertyM., SmithO.P.An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood2000; 96: 3719–3724.
9.
FaustS.N., LevinM., HarrisonO.B.Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med2001; 345: 408–416.
10.
SmithO.P., WhiteB., VaughanD.Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcusinduced purpura fulminans. Lancet1997; 350: 1590–1593.
11.
RintalaE., KauppilaM., SeppalaO.P.Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med2000; 28: 2373–2378.
12.
ClarkeR.C., JohnstonJ.R., MayneE.E.Meningococcal septicaemia: treatment with protein C concentrate. Intensive Care Med2000; 26: 471–473.
13.
WarrenH.S., SuffrediniA.F., EichackerP.Q., MunfordR.S.Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med2002; 347: 1027–1030.
14.
WciselG., JoyceD., GudmundsdottirA., ShasbyD.M.Human recombinant activated protein C in meningococcal sepsis. Chest2002; 121: 292–295.
15.
BachliE.B., VavrickaS.R., WalterR.B., LeschingerM.I., MaggioriniM.Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. Intensive Care Med2003; 29: 337.
